Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
|
| gptkbp:affectsOrgan |
liver
|
| gptkbp:cause |
gptkb:liver_disease
liver cancer cirrhosis |
| gptkbp:causedBy |
gptkb:Hepatitis_C_virus
|
| gptkbp:complication |
gptkb:hepatic_encephalopathy
liver failure portal hypertension |
| gptkbp:diagnosedBy |
HCV RNA test
blood test antibody test |
| gptkbp:firstDescribed |
1989
|
| gptkbp:gene |
genotype 1
genotype 2 genotype 3 genotype 4 genotype 5 genotype 6 |
| https://www.w3.org/2000/01/rdf-schema#label |
Hepatitis C
|
| gptkbp:ICD-10_code |
B17.1
B18.2 |
| gptkbp:mortalityRate |
can be fatal if untreated
|
| gptkbp:prevalence |
over 70 million people worldwide
|
| gptkbp:prevention |
harm reduction for drug users
no vaccine available safe injection practices screening blood products |
| gptkbp:riskFactor |
HIV infection
blood transfusion before 1992 hemodialysis injecting drug use tattooing with unsterile equipment |
| gptkbp:subspecies |
gptkb:acute_Hepatitis_C
gptkb:chronic_Hepatitis_C |
| gptkbp:symptom |
nausea
abdominal pain fatigue jaundice loss of appetite |
| gptkbp:transmissionRoute |
blood-to-blood contact
mother-to-child transmission sharing needles unsafe medical procedures |
| gptkbp:treatment |
gptkb:insulin
antiviral drug direct-acting antivirals ribavirin |
| gptkbp:WHO_priority |
global health problem
|
| gptkbp:bfsParent |
gptkb:disease
|
| gptkbp:bfsLayer |
4
|